Pulse Biosciences to Host Quarterly Investor Conference Call on July 27, 2017
July 11 2017 - 6:30PM
Business Wire
Pulse Biosciences, Inc., (Nasdaq: PLSE) a medical technology
company developing a proprietary therapeutic tissue treatment
platform based on Nano-Pulse Stimulation (NPS), will host its
quarterly investor conference call on July 27, 2017, at 1:30 p.m.
PDT / 4:30 p.m. EDT. The company will provide an update on the
clinical advancement of the PulseTxTM System, including progress of
the clinical study evaluating NPS for the treatment of seborrheic
keratosis (SK), as well as the status of the 510(k) submission from
earlier this year. The company will also provide an update on
recent financial results and developments, including financial
results for the quarter ended June 30, 2017.
Conference Call Details
Pulse Biosciences’ Darrin Uecker, President and Chief Executive
Officer, and other senior executives will host the investor call on
July 27, 2017, at 1:30 p.m. PDT / 4:30 p.m. EDT. For both
“listen-only” participants and those who wish to take part in the
question and answer portion of the call, the telephone dial-in
number is (844) 494-0190 (U.S. toll-free) or (508) 637-5580
(international) using Conference ID 52323044. Listeners will also
be able to access the call via webcast available on the Investor
Section of the company’s website at www.pulsebiosciences.com.
About Pulse Biosciences
Pulse Biosciences is a medical technology company developing a
therapeutic tissue treatment platform based on Nano-Pulse
Stimulation (NPS), a proprietary cell signaling technology. NPS is
a non-thermal, precise, focal drug-free tissue treatment technology
that directly affects the cell membrane and intracellular
structures to stimulate unique behaviors in cells. NPS can initiate
a cell death process that allows for the treatment of tissue cells
with minimal inflammatory response which improves healing outcomes
and supports the replacement of treated tissue cells with healthy
tissue cells. In cancerous lesions, NPS has been shown in
preclinical models to induce immunogenic cell death (ICD) exposing
the unique antigens of the treated cells to the immune system,
resulting in the generation of cytotoxic T-cells and the mounting
of an adaptive immune response targeted against those cells. Pulse
Biosciences is investigating a variety of applications for its
technology that exploits the technology’s unique biologic effect,
including immuno-oncology, dermatology, and veterinary medicine.
More information is available at www.pulsebiosciences.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170711006671/en/
Pulse Biosciences, Inc.Investors:Brian Dow, SVP and Chief
Financial OfficerIR@pulsebiosciences.comorThe Trout GroupMike
Zanoni, 646-378-2924mzanoni@troutgroup.comorMedia:Sam Brown,
Inc.Christy Curran, 615-414-8668christycurran@sambrown.com
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Apr 2024 to May 2024
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From May 2023 to May 2024